Astrazeneca Pharma India Limited · NSE:ASTRAZEN
Astrazeneca Pharma India — Shareholder Meeting (August 2021)
31 slides from Astrazeneca Pharma India's shareholder meeting presentation, Aug 9, 2021
Slide 1: 42nd Annual General Meeting
42nd Annual General Meeting Gagan Singh 9th August 2021
Slide 2: Disclaimer
DISCLAIMER This presentation by AstraZeneca Pharma India Limited (the “Company”) is solely for general information purposes only and may not be taken away, distributed, reproduced, or passed on, directly or indirectly, to any other person or published in whole or in part, in any manner. This present
Slide 3: The Levers That Enable Our Progress
The Levers That Enable Our Progress Strategic priorities Accelerate Be A Great Place To Innovative Science Work Achieve Financial Deliver Growth & Targets TA Leadership 3
Slide 4: Agenda
Agenda 1 Global Update 2 India Macroeconomy & Overview 3 AZPIL Update 4 COVID‐19 Response 5 Therapy Area Update 6 Sustainability 7 Great Place To Work 4
Slide 5: Accelerating the expansion into immunology
Accelerating the expansion into immunology Alexion: immune-mediated rare disease global leader 5 Source: AstraZeneca H1 2021 presentation
Slide 6: Pipeline Progress
Pipeline Progress Highlights from the late-stage development 6 Source: AstraZeneca H1 2021 presentation
Slide 7: FY 2020: total revenue +10%
FY 2020: total revenue +10% New medicines continued to grow 77 Source: AstraZeneca Full year 2020 presentation
Slide 8: COVID-19 Response
COVID-19 Response “We remain steadfast in our continued commitment to changing the course of the pandemic for the people of India. We hope that through increasing vaccinations, humanitarian relief efforts, and critical donations of medicines and needed equipment, India will steadily recover from thi
Slide 9: Continuing response to COVID-19
Continuing response to COVID-19 Vaxzevria and AZD2816 invoiced in H1 2021 by AstraZeneca incl. 97m to the EU 9 Source: AstraZeneca H1 2021 presentation
Slide 10: Agenda
Agenda 1 Global Update 2 India Macroeconomy & Overview 3 AZPIL Update 4 COVID‐19 Response 5 Therapy Area Update 6 Sustainability 7 Great Place To Work 10
Slide 11: Macroeconomic Indicators Healthcare
Macroeconomic Healthcare IPM Indicators Current Healthcare Expenditure (CHE) at 4% of GDP FY20‐21 Impacted by is considered low as per global standards5 • India has registered over 30 M COVID Pandemic infections till date ‐ overwhelming the Health Expenditure Split6 ‐ (%) healthcare facilities in ur
Slide 12: Agenda
Agenda 1 Global Update 2 India Macroeconomy & Overview 3 AZPIL Update 4 COVID‐19 Response 5 Therapy Area Update 6 Sustainability 7 Great Place To Work 12
Slide 13: Committed to impact patient lives with new launches
Committed to impact patient lives with new launches New Drug approvals and Line Extensions Pharmacovigilance • Dapa CKD approval & launch • Adapted to the new regulations in reporting of SAEs to Indian HA • Fasenra complete Approval and launch in India. • Registered more than 150 • Tagrisso‐ADAURA a
Slide 14: Financial Snapshot of FY 2020-21
Financial Snapshot of FY 2020-21 9% revenue growth excluding ticagrelor franchise 14 Source: AZPIL Annual Report 2020‐21
Slide 15: Agenda
Agenda 1 Global Update 2 India Macroeconomy & Overview 3 AZPIL Update 4 COVID‐19 Response 5 Therapy Area Update 6 Sustainability 7 Great Place To Work 15
Slide 16: COVID-19 Response
Like in previous year, our priority is to continue to ensure: COVID-19 Uninterrupted supply of medicines to patients Response Safeguarding the health of adjoining communities Safeguarding the health of our employees 16
Slide 17: Transforming patient lives during the pandemic
Transforming patient lives during the pandemic Over 150+ partners explored and 35+ onboarded to create system of care Objective was to build a system of care that helps company to Impact of System of Care meaningfully engage with HCPs and enable seamless interaction between on patient lives patients
Slide 18: Bringing positive impact on community & business
Bringing positive impact on community & business Unprecedented commitment by employees during challenging times Business Impact Community Impact Field team was quick to adapt an omnichannel approach to connect with the HCPs. Impact‐ 39,000+ remote calls, 1,38,000+ opened emails and 13,000+ unique HC
Slide 19: Agenda
Agenda 1 Global Update 2 India Macroeconomy & Overview 3 AZPIL Update 4 COVID‐19 Response 5 Therapy Area Update 6 Sustainability 7 Great Place To Work 19
Slide 20: AZ is the fastest growing science led oncology company in the country
AZ is the fastest growing science led oncology company in the country* Performance‐ highlights* Lung Franchise Tagrisso is the No.1 lung cancer brand in the country* Women’s Cancer Lynparza is the No.1 Ovarian Cancer brand in the country* Haemato‐ Oncology 1st digitally launched onco. brand in India
Slide 21: Integrating biomarker testing in oncology clinic to redefine cancer care
Integrating biomarker testing in oncology clinic to redefine cancer care The Right The Right Science Diagnostics Awareness of biomarker Local lab partnerships for high identification quality molecular diagnostics Guidelines and local evidence Introduced liquid biopsy, generation affordable Next Gene
Slide 22: CVRM – Shifting focus from treating patients with a single disease
CVRM – Shifting focus from treating patients with a single disease, to addressing overlapping disease areas Adapted from: 22 DIABETES CARE, VOLUME 22, NUMBER 5, MAY 1999, Circulation. 2006;114:2850-2870 Am Heart J. 1991; 121:1244-1263, Diabetes Obes Metab. 2018;20:1102–1110.
Slide 23: Respiratory- progressive growth sustained in Symbicort; Fasenra launched
Respiratory- Despite COVID challenges, progressive growth sustained in Symbicort; Fasenra launched Symbicort Vs Respiratory Market 68% 54% 17% 12% 4% 4% MAT YTD Qtr Symbicort Respiratory 23 Source : IQVIA JUN MAT 2021
Slide 24: Agenda
Agenda 1 Global Update 2 India Macroeconomy & Overview 3 AZPIL Update 4 COVID‐19 Response 5 Therapy Area Update 6 Sustainability 7 Great Place To Work 24
Slide 25: Expanding access & awareness via CSR & digital outreach
Expanding access & awareness via CSR & digital outreach Launch of Phase II of Ganga Godavari Program & ‘New Normal Same Cancer’ campaign The objective of Ganga Godavari Cancer Screening Program for women The objective of ‘New Normal Same Cancer’ campaign was to raise was to conduct a specialized che
Slide 26: AZ India is committed to furthering health care innovation
AZ India is committed to furthering health care innovation Established in 2019 with anchor partners • 14 start ups solutions winning the India Sweden Innovation Healthcare NASSCOM, AIIMS Delhi and AIIMS Jodhpur with a vision of affordable and accessible Challenge being incubated innovation healthcar
Slide 27: Agenda
Agenda 1 Global Update 2 India Macroeconomy & Overview 3 AZPIL Update 4 COVID‐19 Response 5 Therapy Area Update 6 Sustainability 7 Great Place To Work 27
Slide 28: Recognized as a Great Place to Work three years in a row
Recognized as a Great Place to Work three years in a row 28
Slide 29: Recognition for AZ’s efforts during the pandemic
Recognition for AZ’s efforts during the pandemic 29
Slide 30: Key priorities going forward
Key priorities going forward Industry leading organization in scientific leadership & patient centric innovation Big & bold ambition with oncology growth in India Drive launch excellence of new products & indications to accelerate growth Continued focus on building a patient‐centric ecosystem Capabi
Slide 31: Confidentiality Notice
Confidentiality Notice This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or dis
AstraZeneca Pharma India — Shareholder Meeting (August 2021) on 6ix